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Background: The androgen receptor (AR) and its splice variants are critical for castration resistance of prostate cancer.
Results:We have cloned a novel membrane-bound AR splice variant AR8 that is required for optimal activation of AR.
Conclusion: AR8 potentiates AR transcriptional activity and promotes castration resistance.
Significance:Our findings provide new insights into mechanisms by which AR and its variants promote castration resistance.
Progression from the androgen-sensitive to androgen-insen-
sitive (or castration-resistant) stage is themajor obstacle for sus-
tained effectiveness of hormonal therapy for prostate cancer.
The androgen receptor (AR) and its splice variants play impor-
tant roles in regulating the transcription program essential for
castration resistance. Here, we report the identification of a
novel AR splice variant, designated as AR8, which is up-regu-
lated in castration-resistant prostate cancer cells. AR8 is struc-
turally different from other knownAR splice variants because it
lacks a DNA binding domain and therefore, unlikely functions
as a transcription factor on its own. Immunofluorescence stain-
ing revealed that AR8 was primarily localized on the plasma
membrane, possibly through palmitoylation of two cysteine res-
idues within its unique C-terminal sequence. Mutation of these
putative palmitoylation sites in AR8 led to loss of its plasma
membrane localization. In addition,wedemonstrated that over-
expression of AR8 in prostate cancer cells promoted association
of Src and AR with the EGF receptor in response to EGF treat-
ment and enhanced tyrosine phosphorylation of AR. Con-
versely, specific knockdown of AR8 expression in prostate can-
cer cells compromised EGF-induced Src activation and AR
phosphorylation. This effect was accompanied with attenuation
of proliferation and increased apoptosis in prostate cancer cells
cultured in androgen-depleted medium. We also showed that
AR8 was required for optimal transcriptional activity of AR in
response to treatment of both androgen and EGF. Taken
together, our results demonstrate that the membrane-associ-
ated AR8 isoform may contribute to castration resistance by
potentiating AR-mediated proliferative and survival responses
to hormones and growth factors.
Androgen ablation therapy is the most common treatment
for patients withmetastatic prostate cancer. Despite an initially
beneficial response to hormonal therapy, a majority of patients
eventually develop recurrent castration-resistant tumorswhich
are the major cause of mortality related to prostate cancer.
Therefore, understanding mechanisms underlying progression
to a castration-resistant state is critical for developing more
effective treatments for advanced prostate cancer (1, 2).
Development of castration resistance in prostate cancer is a
complicated process due to the nature of its heterogeneity. The
androgen receptor (AR)2 is a key signaling molecule that exerts
physiological effects of androgens in the prostate. It is well
established that AR regulates transcription of androgen-re-
sponsive genes by binding to specificDNAsequences, known as
androgen response elements (1). The human AR gene is com-
posed of at least eight exons. As other members of steroid hor-
mone receptor family, AR contains several functional domains,
including an N-terminal transactivation domain (encoded by
exon 1), a DNAbinding domain (encoded by exons 2 and 3) and
a ligand binding domain (encoded by exons 5–8). Mounting
evidence suggests that AR signaling remains active in castra-
tion-resistant tumors (2). Multiple mechanisms have been pro-
posed for reactivation of AR signaling under androgen-de-
prived conditions, including deregulation of the AR gene,
steroid metabolism enzymes, steroid hormone receptor co-ac-
tivators, as well as growth factors and cytokines (3–5). Ampli-
fication of the AR locus was shown to associate with anti-an-
drogen resistance (6). Autocrine/paracrine factor-induced
tyrosine phosphorylation of AR via Src, ETK/BMX, or Ack-1
kinases may contribute to androgen-independent activation of
AR or sensitize it to respond to low levels of hormone (7–10).
The detailed mechanisms by which AR is phosphorylated by
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these kinases remain elusive. It is also unclear howmembrane-
bound active Src kinase phosphorylates cytosolic AR. On the
other hand, several independent studies showed that a series of
AR splice variants lacking the ligand binding domain are up-
regulated in hormone-resistant prostate cancer cell lines and
tissues and promote castration-resistant growth (11–15). It was
shown that some of these truncated AR isoforms, including
AR3/AR-V7, and ARv567es, play an indispensable role in
androgen-insensitive growth by regulating a unique set of tar-
get genes (12, 14). Expression of one of the major AR splice
variants, AR3, predicts the risk of tumor recurrence after radi-
cal prostatectomy (12). Therefore, deregulation of AR splice
variants may contribute to prostate cancer progression.
In this study, we identified a novel membrane-bound AR
splice variant AR8, which is up-regulated in castration-resis-
tant prostate cancer cell lines. Our data show that AR8 co-op-
erates with the prototype AR to potentiate androgen and
growth factor response in prostate cancer cells by promoting
AR association with EGFR on the plasma membrane and
enhancing AR tyrosine phosphorylation. Our study provides
FIGURE 1. Cloning and expression ofmembrane-boundAR8. A, schematic structure of human AR splice variants. The hatched cassettes indicate the cryptic
exons. Solid thick lines represent the transcribed exon sequences. The AR8 unique amino acid sequence is shown, and putative palmitoylation sites are in red
and underlined. B, expression of AR8 in human prostate tissues. Total RNAwas isolated from 6 benign and 12malignant human prostate tissues and subjected
to reverse transcription-PCR. The primer sets used to amplify AR- or AR8-specific transcripts were described under “Experimental Procedures.” C, relative
expression levels of AR8 in LNCaP, C4-2, and C4-2Bwere quantified using real-time PCR (left). Their expression in two pairs of CW22R xenograft tumors derived
from intact (HS) and castrated (HR) malemicewere also quantified (right). *, p 0.05. Error bars, S.D.D, plasmamembrane localization of AR8. COS-1 cells were
transfected with AR8 or AR8 mutants. Some cells were treated with 25 M 2-bromopalmitic acid (2BP) for 16 h as indicated. Cells were then subjected to
immunofluorescence stainingwith anti-AR (N20) antibody.Nucleuswas visualizedusingDAPI staining. E, effects ofAR8mutationon itsmembrane localization.
COS-1 cells were transfected with the indicated constructs. Membrane fractionation was carried out using the Eukaryotic Membrane Protein Extraction kit
(Pierce). AR protein present inmembrane fractions and total lysateswere detected byWestern blotting (IB) with an anti-AR antibody. EGFR served as a loading
control. F, CWR-R1 cells were infected with lentivirus encoding the shRNA for AR8 (shAR8) or the scrambled control (shCon). At 48 h after infectionmembrane
fractionation was carried out as above. The level of AR8 protein in the membrane or cytosol fraction as well as in the total lysates was detected by Western
blotting with the anti-AR8 antibody. Tubulin serves as a loading control and anti-Hsp90, anti-EGFR to assign the majorities of the marker proteins to their
expected cytoplasmic, membrane fractions respectively.
Membrane-associated AR8 and Castration Resistance
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new insights into understanding the role ofAR splice variants in
development of castration resistance.
EXPERIMENTAL PROCEDURES
Cell Lines and Cell Culture—LNCaP, 22Rv1 and COS-1 cells
were purchased from American Type Culture Collection
(Manassas, VA). Prostate cancer cell lines C4-2, C4-2B, and
CWR-R1 were kindly provided by Drs. D. Tindall and E. Wil-
son, respectively. Cells weremaintained in RPMI 1640medium
with 10%FBS. Transfection experiments were carried out using
FuGENE 6 or FuGENE HD (Roche Applied Science) following
the manufacturer’s instructions.
Cloning and Constructs—The AR8 transcript was amplified
using the 5/3-Rapid Amplification of cDNA Ends (RACE) kit
(Roche Applied Science) as described previously (12). The PCR
products were cloned and sequenced. The full-length AR8
cDNA sequence has been deposited in GenBank (accession
number HM055487). The AR8 coding sequence was subcloned
into a lentiviral expression vector as described previously (8).
AR8 mutation was generated by a PCR-based method
(QuikChange kit; Stratagene) and confirmed by sequencing.
The short hairpin RNAs specific for human AR8 (shAR8) were
constructed based on the Addgene protocol for pLKO.1 using
the following oligonucleotide sequences: shAR8-1, 5-ccggctc-
attatcaggtctatcactcgagtgatagacctgataatgagtttttg-3 and 5-
aattcaaaaactcattatcaggtctatcactcgagtgatagacctgataatgag-3;
shAR8-2, 5-ccgggactctgga aactcattatctcgagataatgagtttccagagt-
ctttttg-3 and 5-aattcaaaaagactctggaaactcattatctcgagataa-
tgagtttccagagtc-3.
Antibodies—The antibodies used in this study includemouse
monoclonal anti-FLAG M2 (Sigma), anti-tubulin (Abm), anti-
EGFR Ab12 (NeoMarkers), anti-EGFR Ab13 (NeoMarkers),
anti-AR (H280), anti-AR (N-20), anti-AR (C-19), anti-AR (441)
(Santa Cruz Biotechnology), and anti-phospho SrcY416 (anti-
pSrc) (Cell Signaling). The phospho-specific antibody for AR
Tyr-534 (anti-pAR) has been described previously (8). The
polyclonal antibody against AR8 was generated by immunizing
two rabbits with the purifiedGST fusion protein containing the
last 33 unique amino acids at the C terminus of AR8 following
the standard protocol (Cocalico Biologicals). The antiserum
was then partially purified by depleting anti-GST through a
conjugated GST column.
Quantitative Real-time PCR—Quantitative real-time PCR
was performed as described previously (12). The sequences of
primers used for AR isoforms are: AR sense, 5-ctactccggacct-
tacggggacatgcg-3 and antisense, 5-gggctgacattcatagccttcaat-
gtgtgac-3; AR8 sense, 5-cgacttcaccgcacctgatg-3 and anti-
sense 5-ctctttcttcgggtatttcgcatg-3; and 18 S rRNA sense,
5-ttgacggaagggcaccaccag-3 and antisense 5-gcaccaccac-
ccacggaatcg-3. Primers for human POV1 and PSA are as
described previously (8). Relative abundance of each target
transcript to 18 S rRNA was quantified using the comparative
Ct. The ratio of AR8 to ARwas calculated by using the Pfaffl
method (16).
Immunofluorescence—Cells were grown on coverslips and
treated as indicated in figure legends and fixed in Lana’s fix
buffer (paraformaldehyde-picric acid fixative) 4% paraformal-
dehyde, 14% (v/v) saturated picric acid, 0.16 M phosphate
buffer, pH 6.9 for 1 h and washed four times with PBS. The
coverslides were blocked in PBS containing 0.3% Triton X-100,
1% BSA, and 1% normal donkey serum for 1 h at room temper-
FIGURE 2. AR8 promotes AR association with EGFR. A, proteins associated with a biotinylated AR8 C-terminal peptide (AR8) or control peptide (Con) were
identified as described under “Experimental Procedures.” Some of the identified proteins are indicated. B, LNCaP cells were infected with lentivirus encoding
AR8 or control vector. At 48 h after infection, cells lysates were immunoprecipitated (IP) with anti-EGFR (left), AR (C-19), or IgG control (right), followed by
Western blot (IB) analysis using the indicated antibodies. C, LNCaP cells were infected with lentivirus encoding AR8, AR8 mutants, or a vector control. At 48 h
after infection, cells lysates were immunoprecipitated with anti-EGFR, followed by Western blot analysis using the indicated antibodies. D, COS-1 cells were
transfectedwith the plasmids encoding ARwith orwithout FLAG-taggedAR8. Cells were then subjected to immunofluorescence staining using anti-AR (C-19)
or anti-FLAG antibodies. The nucleus was visualized using DAPI staining.
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ature. Primary antibody was added and incubated for 1 h at
room temperature. After washing with PBS, the coverslides
were incubated with rhodamine-conjugated anti-mouse and
fluorescein isothiocyanate-conjugated anti-rabbit secondary
antibodies for 1 h at room temperature. Finally, cells were
counterstained with 4,6-diamidino-2-phenylindole (DAPI) to
visualize nuclei before mounting. The coverslides were exam-
ined by using a Nikon Eclipse TE2000-U microscope system.
Luciferase Reporter Assays—Luciferase assays were carried
out as described previously (8). Briefly, at 24 h after transfec-
tion, cells were incubatedwith fresh phenol red-free serum-free
medium for the experiments with growth factors or with phe-
nol red-free medium containing 5% charcoal-stripped FBS for
the experiments using dihydrotestosterone (DHT). The Dual-
Luciferase assays were carried out according to the manufac-
turer’s protocol (Promega). The transfection efficiency was
normalized using a promoter-less Renilla internal control. The
results are presented as the mean relative light units  S.D. of
triplicate samples.
Immunoprecipitation, Biotinylated Peptide Pulldown—Cells
were washed twice with ice-cold PBS and lysed using lysis
buffer (20 mM Tris, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM
EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM
Na3VO4, 1 g/ml aprotinin, 1 g/ml leupeptin, and 1 mM
PMSF) at 4 °C for 30 min. Cell lysates were centrifuged to
remove cell debris before incubation with the antibody at 4 °C
for 1 h. The immunocomplexes were collected using protein
A/G-Sepharose beads. The biotin-GDMRNTRRKRLWKLI-
IRSINSCICSPREAEVPVRQQK-OHpeptide and a biotinylated
control were synthesized by NEO Peptide (Cambridge, MA)
and incubated with CWR-R1 cell extracts. Associated proteins
captured by NeutrAvidin-agarose beads were resolved by SDS-
FIGURE 3. AR8 enhanced AR tyrosine phosphorylation in response to EGF treatment. A, LNCaP cells infected with lentivirus encoding AR8 or a control
vector. At 48 h after infection, cells were treated with EGF for the indicated period of time. Cell lysates were immunoprecipitated (IP) with anti-EGFR followed
byWestern blot (IB) analysis using the indicated antibodies. B, LNCaP cells infectedwith lentivirus encoding AR8, the C558A/C560Amutant, or a control vector
as described in A. The effects of C558A/C560Amutation on AR activity were determined as above. C, specificity of anti-AR8 antibody. COS-1 were transfected
with AR, AR3, AR8 or vector. Total protein lysates were immunoblotted with anti-AR8 and anti-AR, respectively. D, expression of AR8 protein in prostate cells.
Total cell lysates from various prostate cell lines were immunoblotted with anti-AR8. Overexpressed AR8 in LNCaP cells was used as a positive control (Pos
control). Tubulin was used as a loading control. E, CWR-R1 cells infected with lentivirus encoding the shRNA for AR8 (shAR8-1) or a scrambled control (shCon).
At 48 h after infection, cells were serum-starved overnight followed by treatment with vehicle or 100 ng/ml EGF for 30 min. Cell lysates were immunoblotted
using the indicated antibodies.
Membrane-associated AR8 and Castration Resistance
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PAGE and visualized using Coomassie Blue staining. Selected
protein bandswere excised and subjected tomass spectrometry
(MS) analysis as described previously (17).
InVitroCell Proliferation andApoptosis Assays—Cell growth
was determined using a Cell Proliferation Reagent WST-1 Kit
(RocheApplied Science). Briefly, LNCaP orCWR-R1 cells were
grown in 100 l of culture medium into 96-well plates at a
concentration of 3  103 cells/well. The A450 nm and A690 nm
weremeasured using a plate reader. Experimentswere repeated
at least three times. Cell proliferation assays were conducted
using Click-iT™ EdU Imaging kits (Invitrogen). Briefly, cells
were plated on coverslips and incubated with 10 M EdU solu-
tion for 16 h. Cells were then fixed with 3.7% formaldehyde and
incubated with 0.5 ml Click-iT™ reaction mixture for 30 min at
room temperature. The coverslides were examined using a
Nikon Eclipse TE2000-U microscope system. Apoptosis was
determined by the TUNEL assays using In Situ Cell Death
Detection kit (RocheApplied Science). Briefly, cells were grown
on coverslips and fixed with a freshly prepared fixation (4%
paraformaldehyde in PBS, pH 7.4) and then incubated in per-
meabilization solution (0.1% Triton X-100 in 0.1% sodium cit-
rate) for 2 min on ice. TUNEL reaction mixture (50 l) was
added and the sample incubated for 60 min at 37 °C. Finally,
cells were counterstained with DAPI to visualize nuclei before
mounting. The coverslides were examined using a Nikon
Eclipse TE2000-U microscope system.
RESULTS
In our previous study, more than twenty alternatively spliced
AR transcripts were identified in CWR-R1 cells using 3-Rapid
Amplification of cDNA Ends (12). In addition to the variants
reported previously, we have identified a novel AR splice vari-
ant composed of exons 1, 3, and 3b (Fig. 1A). Due to usage of an
alternative splice acceptor site in exon 3 (marked as 3), this
transcript is deduced to encode a protein containing the N-ter-
minal transactivation domain and a 33-amino acid unique
sequence at the C terminus (Fig. 1A and supplemental Fig. 1).
RT-PCR analysis using a pair of primers exclusively recognizing
the unique junction of exon 1 and exon 3 revealed that theAR8
transcript was detectable in a panel of human prostate benign
and tumor tissues (Fig. 1B). Interestingly, the level of AR8 tran-
script is elevated in castration-resistant LNCaP derivatives
(C4-2, C4-2B) and CWR22 xenograft tumors compared with
their hormone-sensitive counterparts (Fig. 1C and supplemen-
tal Fig. 2B). In addition, the level of AR8 transcript relative to
AR appeared to be increased in CWR-R1 cells in response to
treatment with androgen or EGF (supplemental Fig. 2C), sug-
gesting that the relative ratio of AR8 to AR is higher when cell
proliferation is enhanced. AR8 does not contain aDNAbinding
FIGURE 4. The effects of AR8 on EGF- or DHT-induced AR transcription
activity. A, LNCaP cells were infected with lentivirus encoding AR8 or a con-
trol vector. At 16 h after infection, cells were transfectedwith ARR2-luciferase
reporter. At 24hafter transfection, cellswere treatedwith 1nMDHT (left) or 10
ng/ml EGF (right) for 12 hbeforemeasuring luciferase activity. B, CWR-R1 cells
were infected with lentivirus encoding an shRNA for AR8 (shAR8-1 or
shAR8-2) or a scrambled control. Cells were treated with vehicle or 10 ng/ml
EGF for 12 h, and total RNAs were isolated. The relative change of AR, AR3,
AR8, POV1, or PSA transcripts was quantified by real-time PCR. The value of
the control sample without stimulation was set as 1. C, CWR-R1 cells were
treated as in B, except that EGF was replaced with 0.1 nM DHT. The relative
changegeneexpressionwasmonitored as inB. *,p0.05 comparedwith the
control. Error bars, S.D.
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domain, and therefore, it is unlikely to function as a transcrip-
tion factor. The lack of transcription activity for AR8 was con-
firmed by testing a series of reporters driven by androgen
response element-containing promoters (supplemental Fig. 3).
Surprisingly, when AR8 was overexpressed in COS-1 cells, it
mainly localized to the plasma membrane and only sparsely in
some perinuclear compartments (Fig. 1D), whereas AR or
another AR splice variant AR3 was either localized in the cyto-
FIGURE 5. Regulation of prostate cancer cell proliferation and survival by AR8 under androgen-depleted conditions. A, C4-2B, 22Rv1, and CWR-R1 cells
were infected with lentivirus encoding an shRNAs for AR8 (shAR8-1 or shAR8-2) or a control shRNA (shCon). After a 2-week culture in androgen-depleted (CS)
medium, cells were visualized using Coomassie Blue staining (left). CWR-R1 cells were infected with lentivirus encoding the shAR8-1 or a scrambled control
(shCon), followed by measurement of cell proliferation using WST-1 assays at indicated times (center) or the Click-iT™ EdU assay at 48 h after infection (right).
B, LNCaP cells were infected with lentivirus encoding AR8 or a control vector. Cell proliferation was measured using WST-1 assays at the indicated times. C,
CWR-R1 cells were plated on coverslips and infected with lentivirus encoding shAR8-1 or a scrambled control. At 48 h after infection, apoptosis was detected
by TUNEL assays. Apoptotic cells were quantified by counting TUNEL-positive cells in 1000 cells from three independent random fields. *, p 0.05 compared
with the control. Error bars, S.D.
Membrane-associated AR8 and Castration Resistance
OCTOBER 14, 2011•VOLUME 286•NUMBER 41 JOURNAL OF BIOLOGICAL CHEMISTRY 36157
 by guest on D
ecem
ber 9, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
sol or the nucleus of COS-1 cells under the same conditions
(supplemental Fig. 4). Similar results were obtained when AR8
was overexpressed in LNCaP and CWR-R1 cells (supplemental
Fig. 5), suggesting that this protein is preferentially associated
with the plasma membrane. To test whether the unique C-ter-
minal sequence is involved in AR8 membrane targeting, we
deleted this region. Fig. 1D shows that, in the absence of its
unique C terminus, AR8 failed to localize to the plasma mem-
brane. Because post-translational modifications such as myris-
toylation and palmitoylation can regulate the steady-state
localization and function of various peripheral membrane pro-
teins, such as Ras family small GTPases and Src family kinases
(18, 19), we examined whether any amino acid residue in AR8
could be lipidated. A bioinformatic search (20) predicted two
cysteine residues, Cys-558 and Cys-560, located in the AR8
C-terminal region as putative palmitoylation sites. Substitution
of both cysteine residues led to the loss of membrane localiza-
tion of AR8. In addition, treatment of 2-bromopalmitic acid, a
known palmitoylation inhibitor (21), blocked AR8 membrane
association. Similar results were obtained when we examined
the subcellular localization of AR8 and its mutants in mem-
brane fractionation experiments (Fig. 1E). The endogenous
AR8 was also found to be enriched in membrane fraction in
CWR-R1 cells (Fig. 1F). Therefore, AR8 may target the plasma
membrane through palmitoylation of its unique C terminus.
To investigate further the role ofAR8 in prostate cancer cells,
a biotin-conjugated peptide containing the AR8 unique C-ter-
minal sequence was synthesized and used as bait to identify
potential interacting proteins with AR8 in CWR-R1 cells. Our
MS analysis revealed that multiple proteins were associated
with AR8 C-terminal unique sequence (Fig. 2A). Tubulins and
actins are among the most abundant proteins interacting with
the biotinylated peptide, suggesting thatAR8may be associated
with cytoskeletons in prostate cancer cells. This is consistent
with our observation that overexpressedAR8 is primarily local-
ized to the plasmamembrane where these cytoskeletal proteins
are enriched. Interestingly, we also found that the AR8 C-ter-
minal peptide was associated with EGFR andAR.We then con-
firmed the association of AR8 with EGFR and AR in LNCaP
cells overexpressing AR8 by performing co-immunoprecipita-
tion experiments. As shown in Fig. 2B (left), AR8 co-immuno-
precipitated with EGFRwhereas endogenous AR failed to do so
under our experimental conditions. In addition, AR8 appeared
to form a complex with endogenous AR as it was co-immuno-
precipitated by an antibody specific for the C terminus of AR
(Fig. 2B, right).We also examinedwhethermembrane targeting
of AR8 was required for its association with EGFR. As shown in
Fig. 2C, deletion of the C-terminal sequence or mutation of the
FIGURE 6.A, regulation of AR nuclear translocation byAR8. CWR-R1 cells were
infected with lentivirus encoding the shRNA for AR8 (shAR8-1) or the scram-
bled control (shCon). Cells were treatedwith vehicle or 100 ng/ml EGF for 1 h.
The cytoplasmic and nuclear fractions were isolated using the Nuclear and
Cytoplasmic Extractionkit (Pierce). The level ofARprotein ineach fractionwas
determined by Western blotting (IB) using a monoclonal AR antibody (441).
Hsp90 and Poly(ADP-ribose)polymerase were used as markers for the cyto-
plasmic and nuclear fractions, respectively. The intensity of AR in each frac-
tion was quantified by using the software Quantity One. The ratio of nuclear
versus cytoplasmic AR was determined. The value of the EGF-treated control
was set as 1. B, postulated role of AR8 in EGF-induced activation of AR. AR8
may function as a lipid-anchor protein to bring AR to the proximity of the
plasma membrane and promote formation of a dynamic signaling complex
containing EGFR, Src, AR, and AR8 in response to EGF. The level of AR8 could
modulate kinetics of the assembly and dissociation of this complex, allowing
sequential phosphorylation and subsequent nuclear translocation of AR.
Membrane-associated AR8 and Castration Resistance
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palmitoylated cysteine residues completely abolished its asso-
ciation with EGFR. We further demonstrated that overexpres-
sion of AR8 in COS-1 cells enhanced membrane association of
AR detected using the antibody specific for its C terminus (Fig.
2D).
We showed previously that EGF can induce AR tyrosine
phosphorylation via activating Src kinase (8). Because activated
Src kinase is believed to localize to the plasma membrane
whereas AR is largely present in the cytosol or nucleus, we
examined whether the membrane-anchored AR8 could be
involved in this process and serve as a mediator in Src-induced
AR activation. As shown in Fig. 3A, consistent with previous
studies, EGF treatment promoted Src association with EGFR
and induced Src kinase activity, which were further boosted by
AR8. This interaction was accompanied by an increase in asso-
ciation of AR8 and AR with EGFR in response to EGF stimula-
tion. EGF-induced AR association with EGFR was further
enhancedwhenAR8-expressing cells were treatedwith EGF for
15 and 30 min. However, 60–90 min after EGF treatment, dis-
sociation of AR from EGFR appeared to be coupled with a high
level of AR Y534 phosphorylation, which was accelerated in
AR8-expressing cells. In addition, the AR8 C558/C560 mutant
failed to enhance AR tyrosine phosphorylation (Fig. 3B), sug-
gesting thatAR8membrane targeting is required for its activity.
To study further the function of endogenous AR8, we devel-
oped a polyclonal antibody specific for the uniqueC terminus of
AR8 protein. This antibody could detect the overexpressed
AR8 but not AR or AR3 (Fig. 3C). This antibody could also
detect endogenous AR8 protein in a panel of prostate cancer
cell lines including CWR-R1, VcaP, and LNCaP derivatives
(Fig. 3D). Consistent with our RT-PCR data, AR8 expression is
elevated in castration-resistant C4-2 andC4-2B cells compared
with the parental LNCaP cells. Furthermore, knocking down
endogenous AR8 significantly diminished both basal and EGF-
induced AR Y534 phosphorylation (Fig. 3E). Taken together,
these data suggested thatAR8 sensitized prostate cancer cells to
respond to EGF stimulation and enhanced EGF-induced Src
activation and AR Y534 phosphorylation.
Because we showed previously that Y534 phosphorylation
can enhance AR activity in response to growth factors and low
levels of androgen, we examined whether AR8 could promote
AR transcriptional activity. When AR8 was overexpressed in
LNCaP cells, we detected elevated ARR2-driven reporter activ-
ities in response to both androgen and EGF treatment (Fig. 4A).
Conversely, when we knocked down endogenous AR8 expres-
sion in CWR-R1 cells by two independent shRNAs, expression
of AR-regulated genes, including PSA and POV1, was signifi-
cantly diminished in response to both EGF and androgen treat-
ment (Fig. 4, B and C). Furthermore, knockdown of AR8
expression in several hormone-insensitive prostate cancer
lines, including C4–2B, 22Rv1, and CWR-R1, attenuated their
proliferation whereas overexpression of AR8 in hormone-sen-
sitive LNCaP cells promoted cell proliferation under androgen-
depleted conditions (Fig. 5, A and B). AR8 appears to be
required for survival of CWR-R1 cells because inhibition of
AR8 expression by a specific shRNA led to a dramatic increase
in the number of apoptotic cells (Fig. 5C). We showed previ-
ously thatARY534 phosphorylation plays a role in regulation of
AR nuclear translocation in response to EGF treatment. We
therefore examined whether AR8 is required for this process.
As shown in Fig. 6A, knocking down of AR8 expression in
CWR-R1 cells significantly reduced the level of nuclearARpro-
tein. Taken together, these data suggested that AR8 plays a
critical role in both survival and proliferation of prostate cancer
cells under androgen-depleted conditions by modulating Src-
mediated AR tyrosine phosphorylation.
DISCUSSION
Development of castration resistance in prostate cancer is a
complicated process that may involvemultiple genetic and epi-
genetic alterations. Aberrant expression of AR splice variants
may be involved (22). In this report, we showed that deregula-
tion of a novel membrane-associated AR splice variant (AR8)
may play a role in prostate cancer progression by potentiating
proliferative and survival responses to hormones and growth
factors through modulating the activity of AR and possibly
other splice variants. In contrast to AR and other known AR
splice variants, AR8 lacks the DNA binding domain required
for transcription activity and is primarily localized to the
plasma membrane. Therefore, AR8 most likely functions
through a nongenomicmechanism.We showed thatAR8 could
rapidly associate with EGFR in prostate cancer cells in response
to EGF as well as enhanced Src activation and AR tyrosine
phosphorylation. In addition, in the presence of high levels of
AR8, the kinetics of association of phosphorylated AR with
EGFR was also altered. Within the first 30 min of EGF stimula-
tion, AR8 appeared to enhance AR association with EGFR and
allowed membrane-localized Src kinase to phosphorylate AR.
These events were followed by AR8 promoting dissociation of
AR from EGFR when the level of phosphorylated AR reached a
high level at 60–90 min after EGF treatment. We showed pre-
viously that AR could be phosphorylated at multiple tyrosine
residues in Src-overexpressing cells (8). It is possible that sub-
sequent phosphorylation of different tyrosine residues by Src or
other kinases (e.g. ETK/BMX, Ack-1) may attribute to dissoci-
ation ofAR fromEGFR.Our data suggested that EGFR, Src, AR,
andAR8 form a dynamic signaling complex in response to EGF,
and the level of AR8 could modulate kinetics of the assembly
and dissociation of this complex, allowing sequential phospho-
rylation and its subsequent nuclear translocation (Fig. 6B).
Therefore, AR8 may augment androgen and growth factor
responses in prostate cancer cells by bringing AR to the prox-
imity of the plasma membrane and enhancing AR tyrosine
phosphorylation. Future study using antibodies specific for
other tyrosine phosphorylation sites or quantitative MS analy-
sis would be helpful to dissect further the role of AR8 in pro-
moting transient membrane association and phosphorylation
of AR in response to growth factors.
Although AR8 is less abundant than AR and its known splice
variants such asAR3, itmay play an important role in regulating
a rate-limiting step of AR activation induced by growth factors,
possibly androgens as well. Bringing AR to the proximity of the
plasma membrane may enhance its ligand binding efficiency,
especially under androgen-deprived conditions. This possibil-
ity is supported by our observation that knockdown of AR8
expression in prostate cancer cells desensitized androgen
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response. In addition to modulating AR activity by promoting
Tyr-534 phosphorylation, AR8may also regulate the activity of
other AR splice variants. We also detected a reduction of AR3
protein level in AR8 knocked-down CWR-R1 cells.3 However,
such effect does not likely result from nonspecific knockdown
of AR3 transcript because the transcript level of neither AR3
norARwas altered inAR8knocked-downCWR-R1 cells (Fig. 4,
B and C). It is possible that a downstream effector activated by
AR8, such as Src kinases,maymediate this effect bymodulating
the stability of AR3 protein through phosphorylation. This is
currently under investigation. It would be interesting to find
out how AR8 could modulate both AR and AR3 activity and
potential interplays among AR and its various splice variants.
Taken together, our findings provide new insights into
mechanisms by which AR and its splice variants promote cas-
tration resistance in prostate cancer cells. Given that inhibition
of AR8 activity diminished AR tyrosine phosphorylation and
attenuated tumor cell growth under androgen-depleted condi-
tions, targeting the AR8-AR-Src-EGFR complex could poten-
tially serve as a basis for developing new intervention regimen.
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